In the late 19th and early 20th centuries, gastroenterologists and microbiologists became interested the identification of lactic acid-producing bacteria (eg, Boas bacillus) in the stomachs and stools of patients the diagnosis of gastric cancer. [2] [3] [4] Lactic acid in the human stomach and previously been identified in the human stomach during early investigations regarding the chemical nature of gastric acidity (reviewed in 5 ) .
Recently, two studies of a new formulation of Lactobacillus delbrueckii subsp. bulgaricus GLB44 plus a proton-pump inhibitor (PPI)
reported cures of more than 90% of patients with active Helicobacter pylori infections. The first 6 included 24 subjects and gave GLB44 tablets or capsules equal to 15 × 10 9 organisms alone with rabeprazole 20 mg (36 mg omeprazole equivalent) or pantoprazole 20 mg (4.5 mg omeprazole equivalent) twice a day for 7 days followed by GLB44 alone for 3 days. 7, 8 Fecal antigen testing was done after at least 43 days. The cure rate was 91.7% (95% CI = 73%-99%). The second study 9 involved 52 subjects and involved the same dosing The cure rate was 92.3% (95% CI = 81%-97%). Both studies were done in Europe (Bulgaria). This study was a pilot study designed to confirm the effect of GLB44 and a PPI on H. pylori infections.
| ME THODS
This was a pilot study with the sample size predicated on the ability to confirm the results of the two prior studies. 
| Planned analyses
The pilot study design allowed included inclusion of up to 25 subjects and included a stopping rule requiring the study to be halted if it became apparent that it would be impossible to achieve a cure rate of at least 80%. For example, if 0 of the first 10 subjects became UBT negative, the study would be declared a failure (95% C.I. for 0 of 10 = 0% to 21%) and would exclude a successful response of 80% or greater. If there were at least 3 subjects of the first 10 subjected tested negative by UBT (20% success) the study would continue until 25 subjects had completed.
The study was approved by the local Institutional review committee at Baylor College of Medicine and all subjects signed informed consent before entering.
| RE SULTS
Nine H. pylori treatment naïve subjects with mild dyspepsia without any alarm features were entered (3 women, 6 men; average age 30 years, range 26 to 34). All UBTs remained positive, and the study was stopped as it was judged to be impossible to achieve the minimum number of treatment successes required to continue (eg, 3 successes in the first 10 subjects). The cure rate was 0% (95% CI 0%-29%). Even if the remaining projected subjects were successful (ie, 16 additional subjects), the cure rate would have been <85% (ie, 64%). All subjects failing the final UBT were referred to their family doctors for appropriate anti-H. pylori therapy.
Side effects include several loose stool and bloating for days attributed to the milk (vehicle) in one. Another subject experienced 2 days of mild nausea without vomiting and noted that family members had similar viral-like symptoms at neutral pH with the activity being strain-specific. 13 However, we were unable to confirm the prior excellent experience reported by two other groups of investigators. 6, 9 There were some differences between our study and theirs included 1) we used a lower dose of L. delbrueckii subsp. bulgaricus GLB44 (ie, 6 billion vs 15 billion cell/d, 2) we used a powder formulation, whereas they used tablets and capsules. 3) we used a longer duration (14 days) than had been used previously (ie, 10 days), and 4) we used one type of PPI (rabeprazole), whereas prior studies has used a variety of PPIs.
| D ISCUSS I ON
Overall, our results are not inconsistent with studies in which probiotics have been shown to only slightly improve the cure rates with antimicrobial therapies in populations in which antimicrobial resistance had resulted in a decrease in cure rate. 11 On average, the increase in cure rates with triple therapy has been in the range of 10% to 14%. [14] [15] [16] [17] [18] [19] [20] The approach using noninvasive and rapid reliable methods of testing H. pylori status with the UBT or stool antigen testing allows efficient and inexpensive evaluation of different test strategies.
Studies with probiotics used as adjuvant therapy to antibiotics have not shown that any one is superior to others and none has yet proven to be an effective monotherapy. [15] [16] [17] Pilot studies examining 
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